PorTal Access has received U.S. FDA clearance for its FLEXI-PORT family of implantable vascular access ports, marking a commercial milestone for the company’s vascular access technology.

FLEXI-PORT is a power-injectable implantable port system intended for long-term vascular access in adult and paediatric patients. The system is available in 5Fr and 6Fr configurations and can be implanted in either the chest or arm, giving clinicians more flexibility across different patient needs and procedural settings.

This is relevant as implantable vascular access ports are widely used for patients who require repeated venous access, including those receiving chemotherapy, long-term infusion therapy, parenteral nutrition or frequent blood draws. Port design can affect procedural workflow, patient comfort, access reliability and clinician preference.